Movatterモバイル変換

[0]ホーム
URL:

SV2010003704A - MODIFIED POLIPEPTIDES OF FACTOR IX AND USES OF THE SAME - Google Patents

MODIFIED POLIPEPTIDES OF FACTOR IX AND USES OF THE SAME

Info

Publication number
SV2010003704A
SV2010003704ASV2010003704ASV2010003704ASV2010003704ASV 2010003704 ASV2010003704 ASV 2010003704ASV 2010003704 ASV2010003704 ASV 2010003704ASV 2010003704 ASV2010003704 ASV 2010003704ASV 2010003704 ASV2010003704 ASV 2010003704A
Authority
SV
El Salvador
Prior art keywords
factor
modified
polipeptides
same
polypeptides
Prior art date
Application number
SV2010003704A
Other languages
Spanish (es)
Inventor
Alan Brooks
John E Murphy
Marian Seto
Xiaoqiao Jiang
Chandra Patel
Uwe Gritzan
Kornelia Kirchner
Ulrich Haupts
Original Assignee
Bayer Healthcare Llc
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Llc, Bayer Schering Pharma AgfiledCriticalBayer Healthcare Llc
Publication of SV2010003704ApublicationCriticalpatent/SV2010003704A/en

Links

Classifications

Landscapes

Abstract

Translated fromSpanish

SE DIVULGAN POLIPÉPTIDOS MODIFICADOS DEL FACTOR IX, TALES COMO LOS POLIPÉPTIDOS DEL FACTOR IX CON UNO O MÁS SITIOS DE GLICOSILACIÓN INTRODUCIDOS. LOS POLIPÉPTIDOS MODIFICADOS DEL FACTOR IX PUEDEN EXHIBIR UN INCREMENTO DE LA ESTABILIDAD IN VITRO O IN VIVO, TAL COMO UNA SEMIVIDA PLASMÁTICA MAS PROLONGADA. ASIMISMO SE DIVULGAN PROCEDIMIENTOS DE FABRICAR POLIPÉPTIDOS MODIFICADOS DEL FACTOR IX Y A PROCEDIMIENTOS DE USAR MODIFICADOS DEL FACTOR IX PARA, POR EJEMPLO, TRATAR A PACIENTES AFECTADOS POR HEMOFILIA BMODIFIED FACTOR IX POLYPEPTIDES ARE DISCLOSED, SUCH AS THE FACTOR IX POLYPEPTIDES WITH ONE OR MORE INTRODUCED GLYCOSILATION SITES. MODIFIED POLIPEPTIDES OF FACTOR IX MAY EXHIBIT AN INCREASE OF STABILITY IN VITRO OR IN VIVO, SUCH AS A MOST PROLONGED PLASMATIC SEMIVIDE. Likewise, PROCEDURES FOR MANUFACTURING MODIFIED POLIPEPTIDES OF FACTOR IX ARE DISCLOSED AND PROCEDURES FOR USING MODIFIED FACTOR IX FOR, FOR EXAMPLE, TREATING PATIENTS AFFECTED BY HEMOPHILIA B

SV2010003704A2008-04-162010-10-15 MODIFIED POLIPEPTIDES OF FACTOR IX AND USES OF THE SAMESV2010003704A (en)

Applications Claiming Priority (2)

Application NumberPriority DateFiling DateTitle
US12456708P2008-04-162008-04-16
US4596108P2008-04-172008-04-17

Publications (1)

Publication NumberPublication Date
SV2010003704Atrue SV2010003704A (en)2011-02-21

Family

ID=41265284

Family Applications (1)

Application NumberTitlePriority DateFiling Date
SV2010003704ASV2010003704A (en)2008-04-162010-10-15 MODIFIED POLIPEPTIDES OF FACTOR IX AND USES OF THE SAME

Country Status (17)

CountryLink
EP (1)EP2288622A4 (en)
JP (1)JP2011517951A (en)
KR (1)KR20110005862A (en)
CN (1)CN102083856A (en)
AU (1)AU2009244633A1 (en)
BR (1)BRPI0910702A2 (en)
CA (1)CA2721683A1 (en)
CO (1)CO6311000A2 (en)
CR (1)CR11737A (en)
DO (1)DOP2010000311A (en)
EC (1)ECSP10010551A (en)
IL (1)IL208718A0 (en)
MX (1)MX2010011345A (en)
RU (1)RU2010146387A (en)
SG (1)SG189790A1 (en)
SV (1)SV2010003704A (en)
WO (1)WO2009137254A2 (en)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
EP2423305A1 (en)*2006-06-192012-02-29Catalyst Biosciences, Inc.Modified coagulation factor IX polypeptides and use thereof for treatment
JP5613876B2 (en)*2007-10-152014-10-29ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル Human factor IX variants with extended half-life
ES2940323T3 (en)2008-09-152023-05-05Uniqure Biopharma B V Factor IX polypeptide mutant, its uses and a method for its production
KR20220097518A (en)2010-07-092022-07-07바이오버라티브 테라퓨틱스 인크.Factor ix polypeptides and methods of use thereof
AU2013204511B2 (en)*2010-11-032016-03-17Gc Biopharma Corp.Modified factor ix polypeptides and uses thereof
TWI595004B (en)*2010-11-032017-08-11介控生化科技公司 Modified ninth factor multi-peptide and use thereof
US9486507B2 (en)2011-06-102016-11-08Biogen Ma Inc.Pro-coagulant compounds and methods of use thereof
US10656167B2 (en)2011-07-252020-05-19Bioverativ Therapeutics Inc.Assays to monitor bleeding disorders
JP5967631B2 (en)*2012-04-272016-08-10学校法人日本大学 Treatment for epithelial and endothelial damage
WO2014018777A2 (en)2012-07-252014-01-30Biogen Idec Ma Inc.Blood factor monitoring assay and uses thereof
HK1213521A1 (en)2012-09-252016-07-08Bioverativ Therapeutics Inc.Methods of using fix polypeptides
US10391152B2 (en)2012-10-182019-08-27Bioverativ Therapeutics Inc.Methods of using a fixed dose of a clotting factor
US10717965B2 (en)2013-01-102020-07-21Gloriana Therapeutics, Inc.Mammalian cell culture-produced neublastin antibodies
FI2956477T4 (en)2013-02-152024-04-24Bioverativ Therapeutics IncOptimized factor viii gene
JP6387392B2 (en)2013-03-152018-09-05バイオベラティブ セラピューティクス インコーポレイテッド Factor IX polypeptide preparation
WO2015048330A2 (en)2013-09-252015-04-02Biogen Idec Ma Inc.On-column viral inactivation methods
US10584147B2 (en)2013-11-082020-03-10Biovertiv Therapeutics Inc.Procoagulant fusion compound
WO2015085276A1 (en)2013-12-062015-06-11Biogen Idec Ma Inc.Population pharmacokinetics tools and uses thereof
WO2015095809A1 (en)2013-12-202015-06-25Biogen Idec Ma Inc.Use of perfusion seed cultures to improve biopharmaceutical fed-batch production capacity and product quality
AU2015236340B2 (en)2014-03-242020-02-06Bioverativ Therapeutics Inc.Lyophilized factor IX formulations
WO2016004113A1 (en)2014-06-302016-01-07Biogen Ma Inc.Optimized factor ix gene
GB201420139D0 (en)2014-11-122014-12-24Ucl Business PlcFactor IX gene therapy
CA2994547A1 (en)2015-08-032017-02-09Bioverativ Therapeutics Inc.Factor ix fusion proteins and methods of making and using same
SI3411478T1 (en)2016-02-012022-10-28Bioverativ Therapeutics Inc. Optimized factor VIII genes
CN105695616A (en)*2016-04-222016-06-22王冬国Analysis marker for diagnosing thyroid cancer and application thereof
BR112019011115A2 (en)2016-12-022019-10-01Bioverativ Therapeutics Inc methods for treating hemophilic arthropathy using chimeric clotting factors
WO2018144623A1 (en)2017-01-312018-08-09Bioverativ Therapeutics Inc.Factor ix fusion proteins and methods of making and using same
FR3069540B1 (en)2017-07-282019-09-13Universite Claude Bernard Lyon 1 MODIFIED PROTEIN WITH IMPROVED HALF-LIFE
MX2020001593A (en)2017-08-092020-07-13Bioverativ Therapeutics Inc NUCLEIC ACID MOLECULES AND USES THEREOF.
KR20200057051A (en)2017-09-272020-05-25시질론 테라퓨틱스, 인크. Methods, compositions and implantable elements comprising active cells
US11491212B1 (en)2017-09-272022-11-08Catalyst Biosciences, Inc.Subcutaneous administration of modified factor IX polypeptides and treatment of hemophilia B
JP7534219B2 (en)2018-04-042024-08-14シギロン セラピューティクス， インコーポレイテッド Implantable particles and related methods
WO2019195056A1 (en)2018-04-042019-10-10Sigilon Therapeutics, Inc.Methods, compositions, and implantable elements comprising stem cells
DK3793588T3 (en)2018-05-182025-06-16Bioverativ Therapeutics Inc METHODS FOR TREATING HEMOPHILIA A
MX2021001599A (en)2018-08-092021-07-02Bioverativ Therapeutics IncNucleic acid molecules and uses thereof for non-viral gene therapy.
GB201813528D0 (en)2018-08-202018-10-03Ucl Business PlcFactor IX encoding nucleotides
US10842885B2 (en)2018-08-202020-11-24Ucl Business LtdFactor IX encoding nucleotides
UY38389A (en)2018-09-272020-04-30Sigilon Therapeutics Inc IMPLANTABLE DEVICES FOR CELLULAR THERAPY AND RELATED METHODS
WO2020086408A1 (en)2018-10-262020-04-30The United States Of America, As Represented By The Secretary, Department Of Health And Human ServicesA high-yield perfusion-based transient gene expression bioprocess
WO2020215010A1 (en)2019-04-172020-10-22Codiak Biosciences, Inc.Compositions of exosomes and aav
EP4038182A1 (en)2019-09-302022-08-10Bioverativ Therapeutics Inc.Lentiviral vector formulations
WO2021154414A2 (en)2020-01-292021-08-05Catalyst Biosciences, Inc.Gene therapy for hemophilia b with a chimeric aav capsid vector encoding modified factor ix polypeptides
KR20230074703A (en)2020-06-242023-05-31바이오버라티브 테라퓨틱스 인크. Method for removing free factor VIII from preparations of lentiviral vectors modified to express the protein
AU2022226969A1 (en)2021-02-242023-09-14Bluehalo LlcSystem and method for a digitally beamformed phased array feed
CN120659872A (en)2022-10-112025-09-16西吉隆医疗股份有限公司 Engineered cells and implantable devices for treating disease
WO2024081309A1 (en)2022-10-112024-04-18Sigilon Therapeutics, Inc.Engineered cells and implantable elements for treatment of disease

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
FR2638643B1 (en)*1988-11-091991-04-12Transgene Sa DNA SEQUENCE ENCODING HUMAN FACTOR IX OR AN ANALOGUE PROTEIN, EXPRESSION VECTOR, TRANSFORMED CELLS, PROCESS FOR PREPARING FACTOR IX, AND PRODUCTS OBTAINED THEREFROM
WO1999003496A1 (en)*1997-07-211999-01-28The University Of North Carolina At Chapel HillFactor ix antihemophilic factor with increased clotting activity
PL369065A1 (en)*2001-09-042005-04-18Merck Patent GmbhModified factor ix
KR20060034216A (en)*2003-04-092006-04-21넥타르 테라퓨틱스 Hemophilia Treatment by Inhalation of Coagulation Factors
US20060040856A1 (en)*2003-12-032006-02-23Neose Technologies, Inc.Glycopegylated factor IX
WO2005055950A2 (en)*2003-12-032005-06-23Neose Technologies, Inc.Glycopegylated factor ix
EP2423305A1 (en)*2006-06-192012-02-29Catalyst Biosciences, Inc.Modified coagulation factor IX polypeptides and use thereof for treatment
US7700734B2 (en)*2007-01-092010-04-20Shu-Wha LinRecombinant human factor IX and use thereof

Also Published As

Publication numberPublication date
WO2009137254A2 (en)2009-11-12
BRPI0910702A2 (en)2016-07-05
SG189790A1 (en)2013-05-31
MX2010011345A (en)2011-02-23
WO2009137254A3 (en)2010-01-14
IL208718A0 (en)2010-12-30
EP2288622A2 (en)2011-03-02
CR11737A (en)2011-02-07
ECSP10010551A (en)2010-11-30
JP2011517951A (en)2011-06-23
RU2010146387A (en)2012-05-27
KR20110005862A (en)2011-01-19
EP2288622A4 (en)2012-04-18
CN102083856A (en)2011-06-01
CA2721683A1 (en)2009-11-12
DOP2010000311A (en)2011-02-28
AU2009244633A1 (en)2009-11-12
CO6311000A2 (en)2011-08-22

Similar Documents

PublicationPublication DateTitle
SV2010003704A (en) MODIFIED POLIPEPTIDES OF FACTOR IX AND USES OF THE SAME
DOP2012000030A (en) MODIFIED FACTOR IX POLIPEPTIDES AND USES OF THE SAME
CO6331368A2 (en) MODIFIED POLIPEPTIDE FACTORS VII (FVII)
NI200900187A (en) MODIFIED FACTOR VII POLYPEPTIDES AND USES OF THE SAME.
GT201400166A (en) SYNTHETIC APELINE MIMETICS FOR THE CARDIAC INSUFFICIENCY TREATMENT
ECSP12011908A (en) OCTAHIDROPIRROLO [3,4-c] PIRROLOS DISUSTITUIDOS AS
UY34781A (en) MODULATORS OF THE COMPLEMENT ROUTE AND USES OF THE SAME
CY1116424T1 (en) ADENINIS PRODUCTION AS RISK RISK
CL2011002700A1 (en) Highly reliable ingestible event marker and method for its use.
ECSP12012024A (en) COMBINED THERAPY FOR CANCER TREATMENT AND RELATED DIAGNOSTIC TESTS
CL2010001160A1 (en) Compounds derived from 3,8-diazabicyclo [4.2.0] octane and 3,6-diazabicyclo [3.2.0] heptane; pharmaceutical composition; orexin reeptor modulators, useful in the treatment of insomnia.
CL2008001626A1 (en) Compounds derived from fused heterocycles, a pharmaceutical agent that comprises them and their use in the prophylaxis and treatment of cancer.
CL2020000019A1 (en) Iiarn agents for the inhibition of alpha-enac expression and methods of use.
UY35703A (en) ANTIBODIES AGAINST THE INHIBITOR-1 OF THE PLASMINOGEN ACTIVATOR (PAI-1) AND USES OF THE SAME
CR20110630A (en) CARBOXAMIDE COMPOUNDS AND ITS USE AS CALPAIN INHIBITORS
NI201000015A (en) BUPROPION BROMHYDRATE AND THERAPEUTIC APPLICATIONS
DOP2010000251A (en) EFFECTIVE PARAMYXOVIRUS AS ANTITUMORAL
CY1114880T1 (en) MGLU2 AGONISTS
DOP2010000346A (en) 4- (3-CHLORO-2-FLUOROANILINO) DIFUMARATE SALT -7-METOXI-6 - {[1- (N-METILCARBAMOILMETIL) PIPERIDIN-4-IL] OXI} QUINAZOLINE
BR112014028443A8 (en) STERILE COMPOSITION STERILIZED WITH RADIATION
UY29250A1 (en) CYTOTOXIC AGENTS UNDERSTANDING NEW TAXANES MODIFIED IN C-2.-
PA8824601A1 (en) USE OF DRONEDARONA TO PREPARE A MEDICINAL PRODUCT FOR THE TREATMENT OF PATIENTS WITH ARRITMIA
BRPI0719885B8 (en) pegylated peptides as pth receptor modulators, their uses, and composition.
UY32975A (en) AMINOPIRIDINE DERIVATIVES
BR112014013374A2 (en) acamprosate formulations, methods of using it, and the combinations that make up the same
[8]ページ先頭
©2009-2025 Movatter.jp